Bioscience Company Signs Milestone Term Sheet For Joint Disease Treatment

In an unprecedented move that signals a significant leap forward in the treatment of joint diseases, Enveric Biosciences has announced its decision to sign non-binding term sheets for the exclusive out-licensing of new chemical entities. These entities, specifically designed for both pharmaceutical and non-pharmaceutical applications, are set to revolutionize the approach to managing joint disease, offering hope to millions suffering worldwide. $Enveric Biosciences (ENVB.US)$